Phase 3, 1,2,3 prior line of therapy, Dexamethasone+Lenalidomide+Carfilzomib (KRd), Lenalidomide Not-Refractory, Lenalidomide+Dexamethasone (Rd), Proteasome Inhibitors (PI), Relapsed Refractory Multiple Myeloma (RRMM)
### Instruction:
Identify the study with the following condition. 
### Input:
Phase 3, 1,2,3 prior line of therapy, Dexamethasone+Lenalidomide+Carfilzomib (KRd), Lenalidomide Not-Refractory, Lenalidomide+Dexamethasone (Rd), Proteasome Inhibitors (PI), Relapsed Refractory Multiple Myeloma (RRMM) 
### Output:
Popular Name is ASPIRE, Study ID is NCT01080391